The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam, a Cytochrome P450 3A4/P-gp (CYP3A4) Substrate, in Postmenopausal Osteoporotic Women
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Between 45 to 75 years of age
- Postmenopausal women
- Osteoporosis
Exclusion Criteria:
- Use of any known inhibitors of cytochrome P450 3A4/P-gp (CYP3A4) within 14 days or 5 half lives, whichever is longer; or grapefruit juice or grapefruit containing products within 7 days prior to investigational product administration
- Use of any known CYP3A4 inducers within 30 days or 5 half-lives, whichever is longer, prior to investigational product administration
- Use of any herbal medicine with a known impact on CYP3A4 (eg, St. John's wort) within 30 days prior to investigational product administration
- Current use of medications prescribed for osteoporosis treatment
- Use of midazolam within 14 days prior to investigational product administration
- Influenza or other vaccination within 28 days of screening
- Previous exposure to denosumab
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Sonstiges: Midazolam
All 27 subjects will receive midazolam.
|
Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
Andere Namen:
|
|
Aktiver Komparator: Denosumab
Eighteen (18) subjects will receive denosumab.
|
All subjects will receive two oral dose administrations of midazolam.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ratio of Pharmcokinetic (PK) Area Under the Concentration Time Curve (AUC) Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only)
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
|
Estimates of Inter- and Intra-subject Variability for the PK AUC Parameters for Midazolam With Denosumab Group
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
AUC Subject denotes the inter-subject variability, while AUC Residual denotes the intra-subject variability
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
|
Estimates of Inter- and Intra-subject Variability for PK Maximum Observed Plasma Concentration (Cmax) Parameter for Midazolam With Denosumab Group
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
Cmax Subject denotes the inter-subject variability, while Cmax Residual denotes the intra-subject variability
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
|
Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only)
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ratio of PK AUC Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only)
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
|
Estimates of Inter- and Intra-subject Variability for the PK AUC Parameters for Midazolam Only Group
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
AUC Subject denotes the inter-subject variability, while AUC Residual denotes the intra-subject variability.
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
|
Estimates of Inter- and Intra-subject Variability for PK Cmax Parameter for Midazolam Only Group
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
Cmax Subject denotes the inter-subject variability, while Cmax Residual denotes the intra-subject variability.
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
|
Summary of Serum Denosumab Concentration
Zeitfenster: Baseline (day 2 pre-dose) to day 16
|
This table summarizes serum Denosumab for Midazolam with Denosumab group.
The Lower Limit Of Quantification (LLOQ) is 20 ng/mL.
On Day 2 (pre-dose), the true value is below LLOQ, and is treated as 0 in the analysis.
|
Baseline (day 2 pre-dose) to day 16
|
|
Summary of Serum C-Telopeptide Concentration
Zeitfenster: Baseline (day 2 pre-dose) to day 16
|
This table summarizes serum C-Telopeptide (sCTX) concentration raw values for Midazolam with Denosumab group.
|
Baseline (day 2 pre-dose) to day 16
|
|
Summary of Percent Change From Baseline to Day 16 for Serum C-Telopeptide Concentration
Zeitfenster: Baseline (day 2 pre-dose) to day 16
|
This table summarizes percent change from baseline to day 16 for serum C-Telopeptide (sCTX) concentration raw values for Midazolam with Denosumab group.
|
Baseline (day 2 pre-dose) to day 16
|
|
Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only)
Zeitfenster: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
|
From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Stoffwechselerkrankungen
- Erkrankungen des Bewegungsapparates
- Knochenerkrankungen
- Knochenerkrankungen, Stoffwechsel
- Osteoporose
- Osteoporose, postmenopausal
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Depressiva des zentralen Nervensystems
- Anästhetika, intravenös
- Anästhesie, Allgemein
- Anästhetika
- Beruhigende Agenten
- Psychopharmaka
- Hypnotika und Beruhigungsmittel
- Adjuvantien, Anästhesie
- Anti-Angst-Mittel
- GABA-Modulatoren
- GABA-Agenten
- Mittel zur Erhaltung der Knochendichte
- Midazolam
- Denosumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 20101131
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .